Charles River Laboratories International, Inc.
CRL · NYSE
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,004,852 | $1,032,135 | $984,168 | $1,002,549 |
| % Growth | -2.6% | 4.9% | -1.8% | – |
| Cost of Goods Sold | $666,060 | $675,068 | $666,436 | $718,305 |
| Gross Profit | $338,792 | $357,067 | $317,732 | $284,244 |
| % Margin | 33.7% | 34.6% | 32.3% | 28.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $177,589 | $191,549 | $177,799 | $195,708 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $27,404 | $65,384 | $65,264 | $256,223 |
| Operating Expenses | $204,993 | $256,933 | $243,063 | $451,931 |
| Operating Income | $133,799 | $100,134 | $74,669 | -$167,687 |
| % Margin | 13.3% | 9.7% | 7.6% | -16.7% |
| Other Income/Exp. Net | -$46,599 | -$28,716 | -$38,691 | -$49,104 |
| Pre-Tax Income | $87,200 | $71,418 | $35,978 | -$216,791 |
| Tax Expense | $31,644 | $18,725 | $10,100 | -$3,044 |
| Net Income | $54,422 | $52,326 | $25,469 | -$215,699 |
| % Margin | 5.4% | 5.1% | 2.6% | -21.5% |
| EPS | 1.11 | 1.06 | 0.5 | -4.22 |
| % Growth | 4.7% | 112% | 111.8% | – |
| EPS Diluted | 1.1 | 1.06 | 0.5 | -4.22 |
| Weighted Avg Shares Out | 49,213 | 49,149 | 50,677 | 51,138 |
| Weighted Avg Shares Out Dil | 49,426 | 49,316 | 50,853 | 51,138 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,422 | $1,097 | $1,404 | $1,835 |
| Interest Expense | $25,403 | $29,967 | $27,884 | $28,234 |
| Depreciation & Amortization | $85,164 | $119,507 | $120,364 | $102,104 |
| EBITDA | $197,767 | $220,892 | $184,226 | -$86,453 |
| % Margin | 19.7% | 21.4% | 18.7% | -8.6% |